BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

(TheNewswire)

VANCOUVER, BC and LANDERA RANCH, CA March 10, 2026 -- BioVaxys Technology Corp.(CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys") and Adiverna LLC ("Adiverna")announce today that they have entered into a Research Agreement("Agreement") to develop mRNA-based Rabies, Leptospirosis,Feline Infectious Peritonitis (FIV and other mRNA-based vaccines forcompanion animal veterinary applications (dogs and cats).  Thecollaboration utilizes BioVaxys' DPX™ Immune Educating Platform("DPX") formulations with novel proprietary mRNA sequencescoding for protective antigens designed and developed by Adiverna.

Adiverna is pioneering a unique approach in veterinaryhealthcare by leveraging its proprietary artificial intelligencetechnology to design and optimize mRNA sequences for vaccinesspecifically tailored for companion animals. Currently, no mRNAvaccines are approved for these animals, making Adiverna's focuson this area groundbreaking. By utilizing machine learning algorithmsand advanced bioinformatics, Adiverna's AI platform analyzesextensive datasets to identify and predict the most effective mRNAsequences that code for protective broadly cross-neutralizing antigensagainst diseases such as FIV, rabies, and leptospirosis. Additionally,Adiverna's mRNA platform offers significant dose-sparingpotential, reducing the amount of vaccine required while stilleliciting robust immune responses.

The BioVaxys DPX platform is a major innovation invaccine development that offers a solution to limitations faced byvaccines using other antigen delivery methods, such as lipidnanoparticles. The DPX platform presents antigens, or multipleantigens, to the immune system using a novel non-systemic mechanism ofaction that does not release active ingredients at the site of theinjection, but rather forces an active uptake of immune cells anddelivery into the lymphatic nodes. The programming of immune cellshappens in vivo and offers a more efficient approach that mimics thenatural function of the immune system. This "no release"mechanism allows for an active uptake of antigens such as mRNA andother polynucleotides, peptides, proteins, and virus-like particles,into immune cells and lymph nodes for a sustained activation of theimmune system in which the T cell flow is sustained over a longerduration than traditional vaccines.  

Traditional vaccines for companion animals aregenerally effective for either 1 year or 3 years, depending on thespecific product used and local, state, or provincial regulations.While current rabies vaccines usually last one year, subsequentboosters can be labeled for three years of protection.  ADPX-formulated mRNA vaccines would offer significant advantages overtraditional vaccines by delivering superior, longer-lasting immunitywith fewer doses, together with high-level, rapid, and durableneutralizing antibody responses and faster, safer, and more scalablemanufacturing.  A DPX mRNA vaccine would not use viral material andwould have fewer impurities, reducing risks associated with injectingforeign, inactivated viruses, and would incorporate other DPX platformadvantages including non-systemic depot delivery, micro-dosing,excellent shelf-life stability, and clinicallydemonstrated efficacy, safety and tolerability in both human andanimal health use.

There are currently no approved mRNA vaccines forcommercial use in companion animals.  However, the mRNA vaccinemarket is evolving, and there are emerging preclinical studies showingtheir efficacy in producing neutralizing protective immune response intarget animals.  

Kenneth Kovan, President and Chief Operating Officer ofBioVaxys says “Challenges faced by LNP-based vaccine formulationsare it can spill out of the injection site leading to systemicinflammatory responses, with their systemic delivery leading todegradation by nucleases and removal by macrophage phagocytosis.  Dueto their relatively short half-life, LNPs can also show instabilityunder in vivo conditions, and with degradation affecting theirstorage, delivery, and overall efficiency.”  Kovan adds that“Data from proof-of-concept studies of DPX-mRNA formulationsdemonstrate that DPX provides enhanced in vitro and in vivo stabilityof packaged mRNA, attracts a therapeutically unique subset of AntigenPresenting Cells (APCs) to the injection site for targeted uptake ofmRNA by the immune system, and that immunization with DPX containingmRNA induces specific immune responses towards encodedantigens.”

The global rabies veterinary vaccines market forinactivated and modified-live virus vector products is valued atUS$785 million in 2024, and is projected to reach approximately US$1.1billion by 2030, growing at a 5.8% CAGR. Annual sales for canineleptospirosis killed vaccine formulations are part of the broader dogvaccine market, which was valued at approximately $2.10 billion in2025, however short durability, serotype specificity and adversereactions make these vaccines difficult to apply. The FIV vaccinemarket is part of the broader feline vaccines sector, which isprojected to reach USD 3.28 billion by 2034, growing from USD 1.77billion in 2025.

Driven by mandatory pet vaccinations, increasingdisease awareness, and rising pet ownership, the market is dominatedby companion animal vaccination in North America, with the Asia/Pacific region experiencing rapid growth due to increasingvaccination campaigns in countries like India and China.1  

“We are very excited to be working with Adiverna todevelop what could be the world’s first mRNA veterinary vaccine. We believe the clinically proven advantages of the DPX platformformulated with Adiverna’s AI-designed mRNA sequences will providefor a superior product, adds Kovan.  “With demonstrated in vivoproof of concept of DPX mRNA formulations, this ‘proof of product’will further our partnering discussions utilizing DPX mRNAformulations in human therapeutic applications.”

About BioVaxys TechnologyCorp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in BritishColumbia, Canada, is a clinical-stage biopharmaceutical companydedicated to improving patient lives with novel immunotherapies basedon the DPX™ immune-educating technology platform and it'sHapTenix© tumor cell construct platform, for treating cancers,infectious disease, antigen desensitization for food allergy, andother immunological diseases. Through a differentiated mechanism ofaction, the DPX™ platform delivers instruction to the immune systemto generate a specific, robust, and persistentimmune response. The Company's clinical stage pipeline includesmaveropepimut-S (MVP-S), based on the DPX™ platform, in phase IIBclinical development for advanced Relapsed-Refractory Diffuse Large BCell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-Sdelivers antigenic peptides from the survivin family, a set ofwell-recognized cancer antigens commonly overexpressed in advancedcancers, and also delivers an innate immune activator and a universalCD4 T cell helper peptide. MVP-S has been well tolerated and hasdemonstrated defined clinical benefit in multiple cancer indicationsas well as the activation of a targeted and sustained,survivin-specific anti-tumor immune response. BioVaxys is alsodeveloping DPX™+SurMAGE, a dual-targeted immunotherapy combiningantigenic peptides for both the survivin and MAGE-A9 cancer proteinsto elicit immune responses to these two distinct cancer antigenssimultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPAfor peanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.

BioVaxys common shares are listed on the CSE under thestock symbol "BIOV" and trade on the Frankfurt Bourse (FSE:5LB0) and in the U.S. on the OTC Markets (OTCQB: BVAXF). For moreinformation, visit www.biovaxys.com and connect with us on X and LinkedIn.

About ADIVERNA LLC

Adiverna (www.adiverna.com) is an innovativebiopharmaceutical company dedicated to advancing veterinary medicinethrough the development of cutting-edge mRNA-based vaccines andtherapies. Registered in Ladera Ranch, CA, Adiverna focuses onenhancing the health and well-being of companion animals by utilizingits proprietary mRNA technology platform, which enables the design ofprecise and effective immunizations against various infectiousdiseases and conditions.

Leveraging a unique mechanism of action,Adiverna's mRNA vaccines provide the immune system with thegenetic instructions to produce specific antigens, resulting in atargeted and robust immune response. This approach aims to overcomethe limitations of traditional vaccines by offering faster developmenttimes and improved efficacy.

Adiverna's clinical pipeline includes severalpromising candidates, notably its lead mRNA vaccine designed toprotect against common viral infections in pets. This vaccine aims toactivate a strong immune response, providing long-lasting protectionwhile minimizing the risk of adverse effects. Additionally, Adivernais exploring mRNA formulations for combination vaccines that addressmultiple pathogens simultaneously, thereby simplifying vaccinationprotocols for pet owners and veterinarians.

The company is committed to demonstrating the safetyand efficacy of its mRNA vaccines through rigorous clinical trials,ensuring they meet the highest standards of veterinary care.Adiverna's innovative solutions position it at the forefront ofveterinary immunotherapy, with the potential to significantly improvethe lives of companion animals.

Visist www.adiverna.comand connect with us on social media platforms like Xand LinkedIn.

ON BEHALF OF THE BIOVAXYSBOARD

Signed "JamesPassin"
James Passin, Chief ExecutiveOfficer
Phone: +1 740 358 0555

ON BEHALF OF ADIVERNA

Signed “Kirill Kalnin,PhD”

Kirill V. Kalnin, PhD, Founder andChief Technology Officer

Phone: +1 857 262 3580

Cautionary Statements onForward-Looking Information

This news release includes certain"forward-looking information" and "forward-lookingstatements" (collectively "forward-looking statements")within the meaning of applicable securities legislation. Allstatements, other than statements of historical fact, included herein,without limitation, statements relating to the future operating orfinancial performance of the Company, are forward-looking statements.Forward-looking statements are frequently, but not always, identifiedby words such as "expects", "anticipates","believes", "intends", "estimates","potential", "possible", and similar expressions,or statements that events, conditions, or results "will","may", "could", or "should" occur or beachieved. There can be no assurance that such statements will prove tobe accurate, and actual results and future events could differmaterially from those expressed or implied in such forward-lookingstatements.

Forward-looking statements reflectthe beliefs, opinions and projections on the date the statements aremade and are based upon a number of assumptions and estimates,primarily the assumption that BioVaxys will be successful indeveloping and testing vaccines, that, while considered reasonable byBioVaxys, are inherently subject to significant business, economic,competitive, political and social uncertainties and contingenciesincluding, primarily but without limitation, the risk thatBioVaxys' vaccines will not prove to be effective and/ or willnot receive the required regulatory approvals. With regards toBioVaxys' business, there are a number of risks that could affectthe development of its biotechnology products, including, withoutlimitation, the need for additional capital to fund clinical trials,its lack of operating history, uncertainty about whether its productswill complete the long, complex and expensive clinical trial andregulatory approval process for approval of new drugs necessary formarketing approval, uncertainty about whether its DPX platform can bedeveloped to produce safe and effective products and, if so, whetherits vaccine products will be commercially accepted and profitable, the expenses, delays anduncertainties and complications typically encountered by developmentstage biopharmaceutical businesses, financial and developmentobligations under license arrangements in order to protect its rightsto its products and technologies, obtaining and protecting newintellectual property rights and avoiding infringement to thirdparties and their dependence on manufacturing by third parties.

Many factors, both known andunknown, could cause actual results, performance or achievements to bematerially different from the results, performance or achievementsthat are or may be expressed or implied by such forward-lookingstatements and the parties have made assumptions and estimates basedon or related to many of these factors. BioVaxys does not assume anyobligation to update the forward-looking statements of beliefs,opinions, projections, or other factors, should they change, except asrequired by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.